AstraZeneca: H1 FY 2016 Results (AstraZeneca) - Jul 30, 2016 - Anticipated top-line data from P1 trial (NCT02318394) of durvalumab/tremelimumab + MEDI0562 for advanced malignancies in 2017; Anticipated completion of enrollment of P1 trial (NCT02221960) of durvalumab + MEDI6383 for advanced malignancies in H2 2016; Anticipated completion of enrollment of P1 trial (NCT02503774) of durvalumab + MEDI9447 for advanced malignancies in 2018; Anticipated top-line data from P1 trial (NCT02503774) of durvalumab + MEDI9447 for advanced malignancies in 2019
Anticipated enrollment status • Anticipated P1 data • Oncology
|